Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Digna Biotech, S.L. - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 44 | Code: MRS - 7034

 

Global Markets Direct’s, ‘Digna Biotech, S.L. Product Pipeline Review 2015’, provides an overview of the Digna Biotech, S.L.’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of Digna Biotech, S.L.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of Digna Biotech, S.L. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Digna Biotech, S.L.’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Digna Biotech, S.L.’s pipeline products

 

Reasons to buy

 

Evaluate Digna Biotech, S.L.’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Digna Biotech, S.L. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Digna Biotech, S.L.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Digna Biotech, S.L. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Digna Biotech, S.L.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Digna Biotech, S.L. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

 

Table of Contents
 

 

Table of Contents 2
List of Tables 4
List of Figures 4
Digna Biotech, S.L. Snapshot 5
Digna Biotech, S.L. Overview 5
Key Information 5
Key Facts 5
Digna Biotech, S.L. - Research and Development Overview 6
Key Therapeutic Areas 6
Digna Biotech, S.L. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Digna Biotech, S.L. - Pipeline Products Glance 14
Digna Biotech, S.L. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Digna Biotech, S.L. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Digna Biotech, S.L. - Drug Profiles 18
cardiotrophin-1 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
disitertide 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Interferon Alfa-5 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
DB-017 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
DB-02901 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
DB-036 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
DB-039 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
DB-055 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
methylthioadenosine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
oncostatin M 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
P-17 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
DB-027 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Digna Biotech, S.L. - Pipeline Analysis 34
Digna Biotech, S.L. - Pipeline Products by Target 34
Digna Biotech, S.L. - Pipeline Products by Route of Administration 36
Digna Biotech, S.L. - Pipeline Products by Molecule Type 37
Digna Biotech, S.L. - Pipeline Products by Mechanism of Action 38
Digna Biotech, S.L. - Recent Pipeline Updates 40
Digna Biotech, S.L. - Dormant Projects 41
Digna Biotech, S.L. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42

 

Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44


 

List of Tables
 

Digna Biotech, S.L., Key Information 5
Digna Biotech, S.L., Key Facts 5
Digna Biotech, S.L. - Pipeline by Indication, 2015 8
Digna Biotech, S.L. - Pipeline by Stage of Development, 2015 10
Digna Biotech, S.L. - Monotherapy Products in Pipeline, 2015 11
Digna Biotech, S.L. - Partnered Products in Pipeline, 2015 12
Digna Biotech, S.L. - Partnered Products/ Combination Treatment Modalities, 2015 13
Digna Biotech, S.L. - Phase II, 2015 14
Digna Biotech, S.L. - Phase I, 2015 15
Digna Biotech, S.L. - Preclinical, 2015 16
Digna Biotech, S.L. - Discovery, 2015 17
Digna Biotech, S.L. - Pipeline by Target, 2015 35
Digna Biotech, S.L. - Pipeline by Route of Administration, 2015 36
Digna Biotech, S.L. - Pipeline by Molecule Type, 2015 37
Digna Biotech, S.L. - Pipeline Products by Mechanism of Action, 2015 39
Digna Biotech, S.L. - Recent Pipeline Updates, 2015 40
Digna Biotech, S.L. - Dormant Developmental Projects,2015 41
Digna Biotech, S.L., Other Locations 42
Digna Biotech, S.L., Subsidiaries 42

 

List of Figures
 

Digna Biotech, S.L. - Pipeline by Top 10 Indication, 2015 7
Digna Biotech, S.L. - Pipeline by Stage of Development, 2015 10
Digna Biotech, S.L. - Monotherapy Products in Pipeline, 2015 11
Digna Biotech, S.L. - Pipeline by Top 10 Target, 2015 34
Digna Biotech, S.L. - Pipeline by Top 10 Route of Administration, 2015 36
Digna Biotech, S.L. - Pipeline by Top 10 Molecule Type, 2015 37
Digna Biotech, S.L. - Pipeline Products by Top 10 Mechanism of Action, 2015 38

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing